Literature DB >> 24335273

Performance of the Rockall scoring system in predicting the need for intervention and outcomes in patients with nonvariceal upper gastrointestinal bleeding in a Brazilian setting: a prospective study.

Juliana Custódio Lima1, Ciro Garcia Montes, Cristiane Kibune Nagasako, Glaucia Fernanda Soares Ruppert Reis, José Olympio Meirelles Dos Santos, Fabio Guerrazzi, Maria Aparecida Mesquita.   

Abstract

BACKGROUND/AIMS: This prospective study investigated the performance of pre-endoscopy and the complete Rockall scores in predicting the occurrence of adverse outcomes and the need for endoscopic or surgical intervention in patients with nonvariceal upper gastrointestinal bleeding.
METHODS: All 656 consecutive patients who underwent endoscopy due to nonvariceal upper gastrointestinal bleeding between 2007 and 2011 were included. Receiver operating characteristic (ROC) curves were plotted for the outcomes of therapeutic intervention, rebleeding and death. The discriminative accuracy of the risk scores was assessed by the area under the ROC curve.
RESULTS: Endoscopic treatment was performed in 55.2% of the patients. Rebleeding and mortality rates were 7.6 and 3.8%, respectively. The pre-endoscopy Rockall scores showed unsatisfactory accuracy in predicting the need for intervention, rebleeding or death, as shown by the respective area under the ROC curve values of 0.52, 0.52 and 0.65. The accuracy of the complete Rockall score in predicting rebleeding was poor (area under ROC: 0.52), but it was higher for mortality (area under ROC: 0.69).
CONCLUSIONS: The pre-endoscopy Rockall score was not useful for predicting the need for therapeutic intervention or adverse outcomes. The complete Rockall score showed an acceptable performance in predicting mortality, but was unable to predict rebleeding.

Entities:  

Mesh:

Year:  2013        PMID: 24335273     DOI: 10.1159/000356313

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Comparing the Performance of the ABC, AIMS65, GBS, and pRS Scores in Predicting 90-day Mortality Or Rebleeding Among Emergency Department Patients with Acute Upper Gastrointestinal Bleeding: A Prospective Multicenter Study.

Authors:  Shuang Liu; Xiaoming Zhang; Joseph Harold Walline; Xuezhong Yu; Huadong Zhu
Journal:  J Transl Int Med       Date:  2021-06-16

2.  Risk stratifying patients with non-varicosic upper gastrointestinal hemorrhage using the Glasgow-Blatchford score: A case series of 91 patients.

Authors:  Houcine Maghrebi; Hazem Beji; Anis Haddad; Amine Sebai; Samia Safraoui; Maroua Hafi; Asma Laabidi; Mohamed Jouini; Montasser Jamel Kacem
Journal:  Ann Med Surg (Lond)       Date:  2022-05-13

3.  Optimizing the Risk Assessment in Upper Gastrointestinal Bleeding: Comparison of 5 Scores Predicting 7 Outcomes.

Authors:  Tiago Cúrdia Gonçalves; Mara Barbosa; Sofia Xavier; Pedro Boal Carvalho; João Firmino Machado; Joana Magalhães; Carla Marinho; José Cotter
Journal:  GE Port J Gastroenterol       Date:  2018-05-02

4.  Absence of Helicobacter pylori is not protective against peptic ulcer bleeding in elderly on offending agents: lessons from an exceptionally low prevalence population.

Authors:  Yeong Yeh Lee; Nordin Noridah; Syed Abdul Aziz Syed Hassan; Jayaram Menon
Journal:  PeerJ       Date:  2014-02-11       Impact factor: 2.984

5.  Comparison of the Glasgow-Blatchford and Rockall Scores for prediction of nonvariceal upper gastrointestinal bleeding outcomes in Chinese patients.

Authors:  Mingliang Lu; Gang Sun; Hua Huang; Xiaomei Zhang; Youqing Xu; Shiyao Chen; Ying Song; Xueliang Li; Bin Lv; Jianlin Ren; Xueqing Chen; Hui Zhang; Chen Mo; Yanzhi Wang; Yunsheng Yang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Comparison of four scoring systems for risk stratification of upper gastrointestinal bleeding.

Authors:  Hakan Tuncer; Turker Yardan; Hizir Ufuk Akdemir; Talat Ayyildiz
Journal:  Pak J Med Sci       Date:  2018 May-Jun       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.